SARS-CoV-2 vaccines in patients with SLE
Wei Tang, Anca Askanase, Leila Khalili, Joan T. Merrill
Abstract
As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicine2019-20 coronavirus outbreakImmunologyVirologyDiseaseInternal medicineInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchT-cell and B-cell ImmunologyImmunodeficiency and Autoimmune Disorders